Inclusion Criteria:

- Histologically documented Classical Hodgkin's lymphoma that is recurrent or
refractory after standard chemotherapy; core biopsies are acceptable if they contain
adequate tissue for primary diagnosis and immunophenotyping; bone marrow biopsies as
the sole means of diagnosis are not acceptable

- Patients with Hodgkin's lymphoma may have one of the following World Health
Organization subtypes:

- Nodular sclerosis Hodgkin's lymphoma

- Lymphocyte-rich Hodgkin's lymphoma

- Mixed cellularity Hodgkin's lymphoma

- Lymphocyte depletion Hodgkin's lymphoma

- Nodular lymphocyte predominant Hodgkin's lymphoma

- Patients must have relapsed or progressed after at least one prior therapy

- Patients with relapsed or refractory disease following stem cell transplantation are
permitted

- No prior treatment with bendamustine; prior therapy with gemcitabine is permitted

- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

- Measurable disease must be present either on physical examination or imaging studies;
non-measurable disease alone is not acceptable

- Measurable disease: lesions that can be accurately measured in at least two
dimensions as >= 1.0 x 1.0 cm by computerized tomography (CT), PET/CT (positron
emission tomography/CT), or magnetic resonance imaging (MRI)

- Non-measurable disease: all other lesions, including small lesions (less than 1.0 x
1.0 cm) and truly non-measurable lesions; lesions that are considered non-measurable
include the following:

- Bone lesions (lesions if present should be noted)

- Ascites

- Pleural/pericardial effusion

- Lymphangitis cutis/pulmonis

- Bone marrow (involvement by Hodgkin's lymphoma should be noted)

- Non-pregnant and non-nursing; due to the teratogenic potential of these agents,
pregnant or nursing patients may not be enrolled; women and men of reproductive
potential should agree to use an effective means of birth control

- Patients with human immunodeficiency virus (HIV) infection are eligible; patients
with HIV infection must meet the following: No evidence of co-infection with
hepatitis B or C; cluster of differentiation (CD)4+ count >= 400/mm; no evidence of
resistant strains of HIV; on anti-HIV therapy with an HIV viral load < 50 copies HIV
ribonucleic acid (RNA)/mL; no history of acquired immune deficiency syndrome (AIDS)
defining conditions

- Granulocytes >= 1000/μl

- Platelet count >= 75,000/μl

- Creatinine =< 20 mg/dL

- Bilirubin =< 2.0 mg/dL

- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.0 x upper
limits of normal